A Trial Evaluating Toxicity of SBRT and LDRB in Localized Prostate Cancer.

The goal of this clinical trial is to compare SBRT (Stereotactic Body RadioTherapy) to LDRB (Low-Dose Rate Brachytherapy with Iodine-125 seed implant) in patients with low and favourable intermediate-risk prostate cancer. The two main questions it aims to answer are : 1. Does SBRT (Stereotactic Body RadioTherapy) for low and intermediate risk prostate cancer patients will result in less genito-urinary (GU) and gastro-intestinal (GI) toxicities than LDRB (Low-Dose Rate Brachytherapy)? 2. Does prostate cancer patients treated by SBRT have a better quality of life than patients treated by LDRB

Trial Details

NCT ID
NCT06052683
Phase
NA
Sponsor
CHU de Quebec-Universite Laval
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Low-Dose Rate Brachytherapy to the prostate using Iodine-125 seed implant
  • Stereotactic Body Radiation Therapy to the prostate
Locations (sample)
  • Québec, Quebec, Canada|46.81228,-71.21454

Key Eligibility Criteria

  • Histologically confirmed adenocarcinoma of the prostate diagnosed within the last 8 months. Patients on active surveillance with evidence of diseas…
  • Low-risk and favourable intermediate-risk prostate cancer patients are eligible according to the following definitions:
  • Low-risk disease defined as: Clinical stage T1-T2a and Gleason 6 and PSA ≤ 10 ng/mL
  • Favourable intermediate-risk cancer defined by a single NCCN intermediate risk factor:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →